Akari Therapeutics Plc — Director's Dealing 2015

Jan 2, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Celsus Therapeutics Plc. (CLTX)
CIK: 0001541157
Period of Report: 2015-01-01

Reporting Person: Jimenez Pablo (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Ordinary Shares	$0.57	2024-11-01	Ordinary Shares (130000)		Direct
Options to Purchase Ordinary Shares	$0.57		Ordinary Shares (70000)		Direct

Footnotes

F1: 25% of the shares underlying the options vest annually beginning on 11/1/2014.

F2: The shares underlying the options vest upon attainment of certain clinical development, and/or business milestones over the course of the next sixteen (16) months as follows: execution and completion of first interpretable results in an atopic dermatitis trial and filing/acceptance of an investigational new drug application.